Sunovion Pharmaceuticals has launched Lonhala Magnair glycopyrrolate inhalation solution for the treatment of COPD in the US, the company said. Lonhala Magnair, also known as SUN-101/eFlow, was approved by the FDA in December 2017.
In May 2017, the FDA issued a complete response letter to Sunovion’s initial NDA for Lonhala Magnair, which had been accepted for review in October 2016. Sunovion resubmitted the NDA in June 2017.
Sunovion Executive VP and Chief Commercial Officer David Frawley said, “Sunovion is pleased that Lonhala Magnair is now available as a treatment option for people in the US living with COPD. COPD is a serious, progressive respiratory disease affecting millions of Americans. Bringing this product to market exemplifies Sunovion’s commitment to advancing new therapeutic options for people with COPD, especially those seeking nebulized solutions to manage their COPD symptoms.”
Read the Sunovion press release.
